American Journal of Obstetrics & Gynecology
Volume 198, Issue 4 , Pages 370.e1-370.e7 , April 2008

Management of Trichomonas vaginalis in women with suspected metronidazole hypersensitivity

Presented at the 44th Annual Meeting of the Infectious Diseases Society of America, Toronto, ON, Canada, Oct. 12-15, 2006.

  • Donna J. Helms, MPH

      Affiliations

    • Division of STD Prevention, Coordinating Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA
    • Corresponding Author InformationReprints: Donna Helms, DSTDP/CCID/CDC, 1600 Clifton Rd, Mailstop E-02, Atlanta, GA 30329.
    • ,
  • Debra J. Mosure, PhD

      Affiliations

    • Division of STD Prevention, Coordinating Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • W. Evan Secor, PhD

      Affiliations

    • Division of Parasitic Diseases, Coordinating Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • Kimberly A. Workowski, MD

      Affiliations

    • Division of STD Prevention, Coordinating Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA
    • Emory University, Atlanta, GA.

Received 25 May 2007 ,Revised 10 August 2007 ,Accepted 11 October 2007.

References 

  1. Weinstock H, Berman S, Cates W. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004;36:6–10
  2. Sutton MY, Sternberg MR, Koumans E, McQuillan G, Berman S, Markowitz L. Prevalence of Trichomonas vaginalis in the United States, 2001-2002. [abstract 213] In: Program and abstracts of the 2006 National STD Prevention Conference (Jacksonville, FL). 2006;Available at: http://cdc.confex.com/cdc/std2006/techprogram/P11180.HTM.Accessed Dec. 11
  3. Krieger JN, Anagonou S. Trichomonas vaginalis and trichomoniasis. In:  Holmes KK,  Sparling PF,  Mardh PA, et al. editor. Sexually transmitted diseases. 3rd ed.. New York: McGraw-Hill; 1997;p. 587–604
  4. Heine P, McGregor JA. Trichomonas vaginalis: a reemerging pathogen. Clin Obstet Gynecol. 1993;36:137–144
  5. Cates W. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States (American Social Health Association Panel). Sex Transm Dis. 1999;26:S2–S7
  6. Laga M, Alary M, Nzila N, et al. Condom promotion, sexually transmitted diseases treatment, and declining incidence of HIV-1 infection in female Zairian sex workers. Lancet. 1994;344:246–248
  7. McClelland RS, Sangaré L, Hassan WM, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis. 2007;195:698–702
  8. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2006. MMWR Morb Mortal Wkly Rep. 2006;55(RR-11):52–54
  9. Nanda N, Michel RG, Kurdgelashvili G, Wendel KA. Trichomoniasis and its treatment. Expert Rev Anti Infect Ther. 2006;4:125–135
  10. Mishra D, Mobashir M, Zaheer MS. Fixed drug eruption and cross-reactivity between tinidazole and metronidazole. Int J Dermatol. 1990;29:740
  11. Prieto A, De BM, Infante S, Torres A, Rubio M, Olalde S. Recurrent fixed drug eruption due to metronidazole elicited by patch test with tinidazole. Contact Dermatitis. 2005;53:169–170
  12. van der Pol B. Trichomonas vaginalis infection: the most prevalent nonviral sexually transmitted infection receives the least public health attention. Clin Infect Dis. 2007;44:23–25
  13. Pearlman MD, Yashar C, Ernst S, Solomon W. An incremental dosing protocol for women with severe vaginal trichomoniasis and adverse reaction to metronidazole. Am J Obstet Gynecol. 1996;174:934–936
  14. Kurohara ML, Kwong FK, Lebherz TB, Klaustermeyer WB. Metronidazole hypersensitivity and oral desensitization. J Allergy Clin Immunol. 1991;88:279–280
  15. Yu H, Tak-Yin M. The efficacy of povidone-iodine pessaries in a short, low-dose treatment regime on candidal, trichomonal and non-specific vaginitis. Postgrad Med J. 1993;69:S58–S61
  16. Porapakkham S. Metronidazole treatment of vaginal trichomoniasis (II. Oral vs. vaginal therapy). Obstet Gynecol. 1967;29:213–216
  17. Coelho DD. Metronidazole resistant trichomoniasis successfully treated with paromomycin. Genitourin Med. 1997;73:397–398
  18. Poppe WA. Nitroimidazole-resistant vaginal trichomoniasis treated with paromomycin. Eur J Obstet Gynecol Reprod Biol. 2001;96:119–120
  19. Legal HP. The treatment of trichomonas and candida vaginitis with clotrimazole vaginal tablets. Postgrad Med J. 1974;50(Suppl 1):81–83
  20. Chen MY. Acetarsol pessaries in the treatment of metronidazole resistant Trichomonas vaginalis. Int J STD AIDS. 1999;10:277–280
  21. Waters LJ, Dave SS, Deayton JR, French PD. Recalcitrant Trichomonas vaginalis infection—a case series. Int J STD AIDS. 2005;16:505–509
  22. Nyirjesy P, Sobel JD, Weitz MV, Leaman DJ, Gelone SP. Difficult-to-treat trichomoniasis: results with paromomycin cream. Clin Infect Dis. 1998;26:986–988
  23. duBouchet L, Spence MR, Rein MF, Danzig MR, McCormack WM. Multicenter comparison of clotrimazole vaginal tablets, oral metronidazole, and vaginal suppositories containing sulfanilamide, aminacrine hydrochloride, and allantoin in the treatment of symptomatic trichomoniasis. Sex Transm Dis. 1997;24:156–160
  24. Mammen-Tobin A, Wilson JD. Management of metronidazole-resistant Trichomonas vaginalis—a new approach. Int J STD AIDS. 2005;16:488–490
  25. Stern IJ, Hollifield RD, Wilk S, Buzard JA. The anti-monoamine oxidase effects of furazolidone. J Pharmacol Exp Ther. 1967;156:492–499
  26. Narcisi EM, Secor WE. In vitro effect of tinidazole and furazolidone on metronidazole-resistant Trichomonas vaginalis. Antimicrob Agents Chemother. 1996;40:1121–1125
  27. Schwartz J. Tricofuron therapy of Trichomonas vaginitis. Obstet Gynecol. 1956;7:312–314
  28. Walker PP. Arsenical pessaries in the treatment of metronidazole-resistant Trichomonas vaginalis. Int J STD AIDS. 1997;8:473
  29. Swygard H, Seña AC, Hobbs MM, Cohen MS. Trichomiasis: clinical manifestations, diagnosis and management. Sex Transm Infect. 2004;80:91–95

 This study was supported in part by appointment of D.J.H. to the Research Participation Program of the Centers for Disease Control and Prevention, administered by the Oak Ridge Institute for Science and Education.

 The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

 Cite this article as: Helms DJ, Mosure DJ, Secor WE, et al. Management of Trichomonas vaginalis in women with suspected metronidazole hypersensitivity. Am J Obstet Gynecol 2008;198:370.e1-370.e7.

PII: S0002-9378(07)02017-0

doi: 10.1016/j.ajog.2007.10.795

American Journal of Obstetrics & Gynecology
Volume 198, Issue 4 , Pages 370.e1-370.e7 , April 2008

Article Tools

* Image Usage & Resolution